Larimar Pharma - LRMR Net earnings per share growth forecast for next year

Corporate company logo of Larimar Therapeutics (LRMR)

Larimar Therapeutics focuses on developing innovative protein-based therapies for Friedreich's ataxia. Management is currently coordinating optimal dosages of the primary drug with regulators, supported by major funds. Its proprietary protein delivery system creates a closed niche in the treatment of rare neurological disorders. The forward net income trend reflects overheated expectations, with the value fixed at 16.90.

Larimar Pharma (LRMR): Net earnings per share growth forecast for next year from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Larimar Pharma (LRMR)

Fundamental company analysis:LRMR, Larimar Therapeutics
Finished products of Larimar Therapeutics Inc

For the biotech startup Larimar Therapeutics (LRMR), the expected annual EPS growth rate for the coming year serves as an indicator of the market consensus regarding future R&D monetization. This metric measures the percentage change in projected earnings per share, reflecting analyst expectations for drug development efficiency. The calculation is based on aggregated future cash flow models minus operating expenses. In the absence of M&A activity, this trend determines the company's investment attractiveness before its drugs reach the market.

Key competitors

Net earnings per share growth forecast for next year Jazz Pharmaceuticals|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Bio (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa Pharmaceuticals PLC CNTA|Dyne Pharma (DYN) - Expected net earnings per share growth next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Therapeutics, Inc.|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Kempharm ZVRA|Expected earnings per share growth for next year CTNM|Expected net earnings per share growth next year Capricor Therapeutics CAPR|Earnings growth forecast for next year TRDA|Expected earnings per share growth for next year Channel Therapeutics PTHS|Earnings growth forecast for next year MNOV (MediciNova)|Expected earnings per share trend next year SER|BTAI - Net earnings per share growth forecast for next year|promisneurosciences.com (PMN) - Expected earnings per share growth for next year|Apimeds (APUS) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year AEON|Net earnings per share growth forecast for next year NLS Pharma|Expected net earnings per share growth next year bionomics.com.au BNOX|Earnings growth forecast for next year HUGE|RETA (Reata Pharma) - Expected earnings per share trend next year